Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XT 150

Drug Profile

XT 150

Alternative Names: XT 101; XT-150

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xalud Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Gene therapies; Non-opioid analgesics
  • Mechanism of Action Gene transference; Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Phase I Musculoskeletal pain
  • No development reported Amyotrophic lateral sclerosis; Multiple sclerosis; Neuropathic pain

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Parenteral)
  • 28 Nov 2019 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (Parenteral)
  • 28 Nov 2019 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top